More than health risks play a role in compliance with coronavirus measures The risk of COVID-19 is not the only factor that determines compliance with the coronavirus measures; other risks also play a role.
No evidence of more serious illness from COVID-19 among Q fever patients There are no indications that people who previously had Q fever had a more serious course of illness from the coronavirus SARS-CoV-2. This is evident from RIVM research.
Specific group of patients with impaired immunity invited in October for third COVID-19 vaccination From 6 October on, a specific group of people with severely impaired immunity (immunocompromised patients) will receive their invitation for a third vaccination against COVID-19.
Benefits and bottlenecks for early marketing authorisation of new medicines Patients are asking increasingly often for quicker access to new, innovative medicines. This requires a more effective use of flexible marketing authorisation procedures.
European Baseline Report SUSTAIN The SUSTAIN project has published the European baseline report titled ‘Integrated care for older people living at home – Current situation and ambition of sites participating in the SUSTAIN project
Particle contamination on Silimed breast implants poses minimal risk Particles were found on Silimed silicone-based breast implants that should not be there. These included man-made mineral fibres, such as glasswool and rockwool.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
RIVM research basis for historic climate agreement on HFCs Scientific research by RIVM’s Guus Velders stood partly at the basis of the HFC global climate agreement.
Documentary Sea Blind on Dutch Television Sea Blind is a documentary about the impact of shipping on the environment, especially on the Arctic Sea.
Shortcomings in technical documentation of both existing and new blood glucose meters RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.